SUBSCRIBE
SUBSCRIBE

Janssen Pharmaceutical Inc.

NEWS
Zeposia recieved top line results in the ulcerativ
Drug Development
Stelara’s Efficacy in Crohn’s Continues to Show in Three-Year Study
At the 26th United European Gastroenterology Week (UEGW) congress in Vienna, Janssen presented three-year data from the IM-UNITI study, which demonstrates the continued efficacy of Stelara (ustekinumab) in improving clinical remission rates.
October 24, 2018
 · 
3 min read
 · 
Alex Keown
Courtesy josefkubes/Getty Images_John Reed_courtes
Biotech Bay
J&J’s JLABS Incubators Show off Success of First Six Years
It has been six years since Johnson & Johnson first launched its JLABS incubators for the life science industry with a vision of providing assistance to startups that could potentially bring about a new paradigm of care for patients.
October 19, 2018
 · 
2 min read
 · 
Alex Keown
Zeposia recieved top line results in the ulcerativ
Drug Development
Stellar Phase III Data from Janssen’s Stelara
New late-stage data released by Janssen shows that a single dose of Stelara can induce clinical reemission and response in adult patients with moderate to severe ulcerative colitis who have not had positive response from previous treatment options.
October 9, 2018
 · 
3 min read
 · 
Alex Keown
Courtesy josefkubes/Getty Images_John Reed_courtes
Business
Arrowhead Goes All in With J&J to Develop Hep B Drug for $3.7B
Arrowhead announced a deal with Johnson & Johnson that could conceivably be worth over $3.7 billion, with J&J agreeing to pick up a minor stake in the company, including the task of cultivating and promoting its ARO-HBV Hepatitis B drug.
October 4, 2018
 · 
3 min read
 · 
Elizabeth Glasure
Drug Development
HIV Treatments That Could Make Redfield’s Prediction a Reality to Defeat AIDS Epidemic
In April, Dr. Robert Redfield, the new head of the CDC, boldly predicted that the AIDS epidemic can be defeated by 2025. This morning Merck, Janssen and Gilead all released clinical data for HIV treatments that could make Redfield’s prediction a reality.
October 4, 2018
 · 
3 min read
 · 
Alex Keown
Business
Johnson & Johnson Announces New Collaboration to Advance Novel Vaccine for MERS
New collaboration with Coalition for Epidemic Preparedness Innovations (CEPI) and The Jenner Institute is latest example of Johnson & Johnson’s ongoing commitment to global pandemic preparedness efforts
September 30, 2018
 · 
8 min read
Business
MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC, has initiated a phase 3 clinical trial of guselkumab in pediatric patients suffering from chronic plaque psoriasis.
September 28, 2018
 · 
4 min read
Business
J&J Terminates Imetelstat Collaboration and Licensing Deal with Geron
Geron Corporation, located in Menlo Park, Calif., announced that Janssen Biotech, a Johnson & Johnson company, had terminated their 2014 Collaboration and License Agreement.
September 27, 2018
 · 
3 min read
 · 
Mark Terry
Business
Molecular Templates and Takeda to Take on Multiple Myeloma in Deal Worth up to $632 Million
Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals.
September 20, 2018
 · 
2 min read
 · 
Alex Keown
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Drug Development
Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
October 2, 2019
 · 
19 min read
FDA
FDA Approves New Drug to Treat Diabetes-Related Kidney Disease
September 30, 2019
 · 
2 min read
FDA
U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD
September 30, 2019
 · 
16 min read
Drug Development
Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (apalutamide)
September 27, 2019
 · 
17 min read
FDA
Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma
September 26, 2019
 · 
22 min read
FDA
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
September 17, 2019
 · 
15 min read
Drug Development
New DARZALEX® (daratumumab) Data from GRIFFIN Study Show High Response Rate and Depth of Response in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant-Eligible
September 15, 2019
 · 
24 min read
Drug Development
New Head-to-Head Phase 3 Study Data Show Ponesimod Superiority Versus Aubagio® (teriflunomide) 14 mg in Adults with Relapsing Multiple Sclerosis (MS)
September 11, 2019
 · 
9 min read
Drug Development
New Data from SPRAVATO™ (esketamine) CIII Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
September 9, 2019
 · 
18 min read
Drug Development
Janssen Reports Positive Top-line Phase 3 Study Results of Investigational, Long-acting Injectable HIV Treatment Regimen Administered Every Two Months
August 22, 2019
 · 
5 min read
Load More